TGFB1 and neoplasm: In tumor cells, activated ANO1 promoted TGF-β production and release, which increased cancer-associated fibroblasts (CAFs) infiltration and inhibited accumulation of CD8+T cells, leading to immunotherapeutic resistance to anti-PD-1 antibody in GI cancers (9).